Given a passage, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

[EX Q]: One variant of multiple endocrine neoplasia type 1 (MEN1) is defined by sporadic tumors of both the parathyroids and pituitary. The prevalence of identified MEN1 mutations in this variant is lower than in familial MEN1 (7% vs. 90%), suggesting different causes. Recently, one case of this variant had a germline mutation of p27(Kip1)/CDKN1B.', 'The objective was to test p27 in germline DNA from cases with tumors of both the parathyroids and pituitary.', 'Medical record review and sequence analysis in DNA were performed.', 'This study involved an inpatient and outpatient referral program for cases of endocrine tumors.', 'Sixteen index cases had sporadic tumors of two organs, both the parathyroids and the pituitary. There were 18 additional index cases with related features of familial tumors. Five subjects were normal controls. No case had an identified MEN1 mutation.', 'Clinical status of endocrine tumors was tabulated. Sequencing of germline DNA from index cases and control cases for the p27 gene was performed by PCR.', 'Endocrine tumor types and their expressions were measured, as were sequence changes in the p27 gene.', 'Tumor features were documented in index cases and families. One p27 germline single nucleotide change was identified. This predicted a silent substitution of Thr142Thr. Furthermore, there was a normal prevalence of heterozygosity for a common p27 polymorphism, making a large p27 deletion unlikely in all or most of these cases.
[EX A]: Does the parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually have causes other than p27Kip1 mutations?

[EX Q]: The Cochrane Central Register of Controlled Trials, PubMed Medline and Latin American and Caribbean Health Science literature databases were searched, and searches made by hand of identified papers, to source relevant data. (BIOSIS Previews) were searched. There were no language restrictions.', 'Studies were evaluated by two reviewers independently. Only clinical trials were included that were published in the English, Spanish and Portuguese languages and were performed on humans. Articles were excluded when the examiners were not calibrated; when they did not compare manual and electronic probing techniques; when they did not measure the clinical attachment level (CAL); and when the subjects did not present destructive periodontal disease or had already received periodontal treatment.', 'The quality of the identified studies was assessed and standardised data extracted. Only two studies met all the selection criteria so no meta-analysis was performed.', 'Only two of the 37 identified articles were included in the review. The results of these two studies showed that the mean variance and the absolute mean difference between CAL measurements for the two types of probes were not statistically different.
[EX A]: Do manual and electronic probes have similar reliability in the measurement of untreated periodontitis?

[EX Q]: Results from GOG 178 showed a prolongation of progression-free survival (PFS) with the immediate use of chemotherapy (CT) following a complete clinical response (CR) in patients with stage III-IV ovarian cancer. We wanted to evaluate our strategy of reserving second line (2nd line) chemotherapy to the time of clinical recurrence by determining PFS intervals following first, second, and third line agents and to compare these finding to results of GOG 178.', 'We conducted a retrospective parallel study to GOG 178 using identical criteria for PFS definitions. Patients (pts) with stage III-IV cancer achieving a CR following surgery and five to eight cycles of platinum-based CT were identified. Patients not obtaining a CR and those with a CR who underwent second look surgery were excluded. Rather than immediately beginning consolidation CT after CR, second line agents were started at recurrence and were followed by a third line when pts progressed. Clinical-pathologic characteristics were abstracted, and time intervals including time to recurrence, time to use of second line CT, time to use of third line (3rd line) CT, and survival were recorded. Time intervals were studied by Kaplan-Meier method.', 'Of 217 reviewed pts (1991-2001), 59 eligible pts were identified. Forty-nine patients had stage III disease and ten had stage IV. At completion of surgery, 44 were optimally debulked. With a median follow-up of 51 months, the median PFS (from CR) of all patients was 20 months. At 5 years, 36% of pts remain disease-free, and 66% of pts are alive. Twenty-three pts have not received second line agents, and thirty-six have received them. For all pts, the median time from CR to start of second line chemotherapy was 21 months, and the median time to start of third line agents was 43 months. Recurrences occurred after 6 months from completion of first line (1st line) therapy in 87% of cases and after 12 months in 50%.
[EX A]:
Is timing n't everything : an analysis of when to start salvage chemotherapy in ovarian cancer?